Business Context and Reporting Period
This Form 8-K is a current report filed by PharmAthene, Inc. (not Altimmune, Inc.) on December 9, 2015, covering events that occurred on December 3, 2015. The filing addresses Item 5.02 regarding the appointment of certain officers and compensatory arrangements.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data point disclosed is the closing price of the Company's common stock on the NYSE MKT on the grant date, which was $1.66 per share.
Material Changes
The material change reported is the approval of a retention plan and equity awards for Philip MacNeill, the Company's Vice President, Chief Financial Officer, Treasurer, and Secretary. This represents a new compensatory arrangement rather than a change in operational performance.
Management Commentary and Unusual Items
- Retention Plan: Approved a 10% cash bonus contingent on Mr. MacNeill remaining employed without termination for cause or resignation for good reason prior to December 31, 2016.
- Restricted Stock: Granted 25,000 shares of restricted stock. Vesting is split 50% on December 3, 2016, and 50% on December 3, 2017, with potential acceleration under specific circumstances.
- Stock Options: Granted options to purchase 70,625 shares of common stock. Vesting occurs over 3 years: 25% on the grant date, and 25% annually on the first, second, and third anniversaries.
Investor Verification Checklist
- Verify the exact vesting conditions and acceleration clauses in the restricted stock agreement.
- Confirm the total number of outstanding shares and the dilution impact of the 70,625 new options and 25,000 restricted shares.
- Review the Company's cash position to assess the ability to fund the potential 10% cash bonus.
- Check for any subsequent filings regarding Mr. MacNeill's employment status or changes to the compensation plan.